Related Experiment Videos
Childhood and adolescent diabetes.
David B Dunger1, Fiona M Regan, Carlo L Acerini
1Department of Paediatrics, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Endocrine Development
|May 10, 2005
Summary
Children with type 1 diabetes mellitus often have abnormal insulin-like growth factor-I (IGF-I) levels. IGF-I replacement therapy shows promise for improving metabolic control and reducing complications, but requires further study.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Pediatric Diabetes
Background:
- Children and adolescents with type 1 diabetes mellitus (T1DM) exhibit altered circulating levels of insulin-like growth factor-I (IGF-I), IGF binding protein 3 (IGFBP-3), and IGF binding protein 1 (IGFBP-1).
- These hormonal imbalances are linked to relative hypoinsulinaemia and hepatic growth hormone (GH) resistance, potentially exacerbating insulin resistance during puberty.
- Elevated GH and low IGF-I levels are implicated in the pathogenesis of microangiopathic complications, including renal hypertrophy and microalbuminuria.
Purpose of the Study:
- To evaluate the efficacy and safety of IGF-I replacement therapy in managing T1DM.
- To assess the impact of IGF-I therapy on GH secretion, insulin sensitivity, and glycemic control.
- To investigate the potential of combined recombinant human IGF-I/rhIGFBP-3 therapy for improved tolerability and reduced free IGF-I exposure.
Main Methods:
- Review of early studies using recombinant human IGF-I (rhIGF-I) for T1DM treatment.
- Analysis of pilot studies employing a combination of rhIGF-I and rhIGFBP-3 in T1DM patients.
- Assessment of short-term and long-term outcomes, including hormonal levels, metabolic parameters, and complication development.
Main Results:
- Short-term rhIGF-I administration reduced GH hypersecretion, improved insulin sensitivity, and decreased insulin requirements.
- Longer-term rhIGF-I use led to improved HbA1c levels but was associated with retinopathy at higher doses.
- Pilot studies with rhIGF-I/rhIGFBP-3 confirmed IGF-I replacement efficacy and demonstrated better tolerability with potentially lower free IGF-I levels.
Conclusions:
- IGF-I replacement therapy holds potential for managing T1DM, offering benefits in metabolic control and complication reduction.
- Combined rhIGF-I/rhIGFBP-3 therapy appears to be a safer and more tolerable approach compared to rhIGF-I alone.
- Further long-term clinical studies are necessary to fully establish the safety and efficacy of the IGF-I/IGFBP-3 combination in T1DM management.